Use of Insulin in the treatment of diabetes mellitus

Slides:



Advertisements
Similar presentations
DIABETES MELLTIUS Dr. Ayisha Qureshi Assistant Professor MBBS, MPhil.
Advertisements

Insulin Diabetes Outreach (June 2011). 2 Insulin Learning outcomes >Understand the difference between insulin therapy in type 1 diabetes as compared to.
Islets of Langerhan. Prof. K. Sivapalan Islets of Langerhan2 Histology. A cells 20 % [glucogon] B cells 50% [Insulin] D cells 8% [somatostatin]
Diabetes Mellitus.
Control of Blood Sugar Diabetes Mellitus. Maintaining Glucose Homeostasis Goal is to maintain blood sugar levels between ~ 70 and 110 mg/dL Two hormones.
Pancreatic Hormones Glucagon Insulin.
Diabetes. Diabetes Mellitus Disease in which the body doesn’t produce or properly use insulin, leading to hyperglycemia.
Chapter 36 Agents Used to Treat Hyperglycemia and Hypoglycemia.
Insulin therapy.
Metabolic effects of Insulin and Glucagon Metabolism in the Well fed state Metabolism in the Starvation and Diabetes Mellitus Integration of Metabolism.
CMT Training The Center for Life Enrichment Resource: MTTP Student Manual.
Chapter 24 Chapter 24 Exercise Management.  Diabetes is a chronic metabolic disease characterized by an absolute or relative deficiency of insulin that.
DIABETES AND HYPOGLYCEMIA. What is Diabetes Mellitus? “STARVATION IN A SEA OF PLENTY”
Diabetes Mellitus (Lecture 2). Type 2 DM 90% of diabetics (in USA) Develops gradually may be without obvious symptoms may be detected by routine screening.
Nutrition and Metabolism Negative Feedback System Pancreas: Hormones in Balance Insulin & Glucagon Hormones that affect the level of sugar in the blood.
Use of Insulin in treatment of diabetes mellitus Prof. Hanan Hagar.
content sugar glucose Sources Absorption Diabetes Metabolism OF Carbohydrate The control of blood sugar Insulin Diagnosis of Diabetes Sugar level in the.
Chronic elevation of blood glucose levels leads to the endothelium cells taking in more glucose than normal damaging the blood vessels. 2 types of damage.
Management of diabetic ketoacidosis Prof. M.Alhummayyd.
Use of Insulin in the treatment of diabetes mellitus Prof. Hanan Hagar.
Management of diabetic ketoacidosis (DKA) Prof. M.Alhummayyd.
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA Part 2.
Endocrine Physiology The Endocrine Pancreas Dr. Khalid Al-Regaiey.
INSULIN & ORAL HYPOGLYCEMIC AGENTS.
Diabetes Update: Michael Gottschalk, M.D, Ph.D.
Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.
ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.
Chapter Exercise and Diabetes Dixie L. Thompson C H A P T E R.
Diabetes mellitus.
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
 Insulin is a peptide hormone released by beta cells when glucose concentrations exceed normal levels (70–110 mg/dL).  The effects of insulin on its.
Diabetes Mellitus Part 1 Kathy Martin DNP, RN, CNE.
Management of diabetic ketoacidosis and hypoglycemia Prof. Hanan Hagar.
Use of Insulin in the treatment of diabetes mellitus Prof. M.Alhumayyd.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
Use of Insulin in treatment of diabetes mellitus Prof. Hanan Hagar.
Diabetes Mellitus ENDO 412. Overview DM is a heterogeneous group of syndromes characterized by an elevation of fasting blood glucose caused by absolute.
Diabetes 101 for Kids Sarah Gleich. What is Diabetes???  Diabetes is a disorder of metabolism- the way our body processes and uses certain foods, especially.
DIABETES MELLITUS. Diabetes mellitus (DM) is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. DM is associated.
Use of Insulin in the treatment of diabetes mellitus
Control of Blood Sugar Diabetes Mellitus.
Diabetes mellitus.
Integration of Metabolism
Management of diabetic ketoacidosis and hypoglycemia
DIABETES MELLITUS DR HEYAM AWAD FRCPATH.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
Diabetes Mellitus (DM)
Chapter 7 Metabolic syndrome
Estimation of blood glucose in diabetes mellitus
Diabetes Mellitus Nursing Management.
Practicals – experimental diabetes mellitus in laboratory animal
Alisa Foote SDSU School of Nursing 10/14/11.
Diabetes Mellitus Nursing Management.
Management of diabetic ketoacidosis
Regulating Blood Sugar
Endocrine System KNH 411.
Use of Insulin in the treatment of diabetes mellitus
Management of diabetic ketoacidosis and hypoglycemia
Drugs for Diabetes Mellitus
Endocrine System KNH 411.
Endocrine System KNH 411.
Diabetes Mellitus Passant Mohammed Faculty of science Biochemistry.
Drug Therapy for Diabetes Mellitus
Endocrine System KNH 411.
Endocrine System KNH 411.
Endocrine System KNH 411.
Hormonal Regulation of Carbohydrates
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Insulin in Type 2 Diabetes
Presentation transcript:

Use of Insulin in the treatment of diabetes mellitus Prof. M.Alhumayyd

Diabetes mellitus Is a chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied with insulin resistance. Fasting plasma glucose(no food for 8 hrs) <100 mg/dl(5.6 mmol/l)= Normal 100-125 mg/dl(5.6-6.9 mmol/l) = Prediabetes 126 mg/dl (7 mmol/l) or higher on 2 separate tests = Diabetes

Complications of diabetes Cardiovascular problems Micro-and macro-vascular complications Renal failure (nephropathy). Blindness (retinopathy). Neuropathy. Risk of foot amputation

Types of diabetes mellitus Type I due to autoimmune or viral diseases Type II due to obesity, genetic factors

Characteristic Type 1 Type 2 Onset (Age) Usually during childhood or puberty Usually over age 40 Type of onset Abrupt Gradual Prevalence 10-20% 80-90 % Genetic predisposition Moderate Very strong Defects β-cells are destroyed β-cells produce inadequate quantity of insulin Endogenous insulin Absent Present (not enough) Insulin resistance absent present Nutritional status Usually thin Usually obese Ketosis Frequent Usually absent Clinical symptoms Polyuria,Polydipsia, polyphagia, Wt loss Often asymptomatic Related lipid abnormalities Hypercholesterolemia frequent Cholesterol & triglycerides often elevated Treatment Insulin Oral hypoglycemics±insulin

Type I Diabetes β-cells are destroyed. absolute deficiency of insulin. Treated by insulin.

Effects of insulin 1.Carbohydrate Metabolism Lowers of blood glucose by:  glucose uptake & utilization  Glycogen synthesis  Conversion of carbohydrate to fats.  Gluconeogenesis.  Glycolysis (muscle).

2. Fat Metabolism Liver: Adipose Tissue:  Lipogenesis.  Lipolysis. Inhibits conversion of fatty acids to keto acids. Adipose Tissue:  Triglycerides storage.  Fatty acids synthesis.  Lipolysis

3. Protein Metabolism Liver:  protein catabolism. Muscle:  amino acids uptake.  protein synthesis. glycogen synthesis (glycogenesis). 4. Potassium  potassium uptake into cells.

IV. potassium  potassium uptake into cells.

Types of insulin preparations Vary in onset and duration of action: 1.Ultrashort acting insulins e.g. Lispro, aspart very fast onset and short duration 2. Short acting insulins (Regular)e.g.Humulin R fast onset and short duration. 3. Intermediate acting insulin e.g. NPH, lente slow onset and relative long duration. 4. Long acting e.g. glargine, detemir slow onset and long duration.

e.g. Insulin lispro,Insulin aspart Ultra-short acting insulins e.g. Insulin lispro,Insulin aspart Clear solutions at neutral pH. Monomeric analogue** Fast onset of action (0-15 min) S.C. (5 min no more than 15 min before meal). Peak 30-90 min after injection Short duration of action (3-5 h) 2-3 times/day Uses: Control postprandial hyperglycemia(s.c.) & emergency diabetic ketoacidosis(i.v).

Short acting insulins (regular insulin) Clear solutions at neutral pH. Hexameric analogue. Onset of action 30-45 min (s.c.). Peak 2-4 h. Duration 6-8 h. Uses: Control postprandial hyperglycemia(s.c) &emergency ketoacidosis(i.v.).

Short-acting (regular) insulins e.g. Humulin R, Novolin R Uses postprandial hyperglycemia & emergency diabetic ketoacidosis Physical characteristics Clear solution at neutral pH chemistry Hexameric analogue Route & time of administration S.C. 30 – 45 min before meal I.V. in emergency (e.g. diabetic ketoacidosis) Onset of action 30 – 45 min ( S.C ) Peak level 2 – 4 hr Duration 6 – 8 hr Usual administration 2 – 3 times/day or more Ultra-Short acting insulins e.g. Lispro, aspart, glulisine postprandial hyperglycemia & emergency diabetic ketoacidosis Clear solution at neutral pH Monomeric analogue S.C. 5 min (no more than 15 min) before meal I.V. in emergency (e.g. diabetic ketoacidosis) 0 – 15 min ( S.C ) 30 – 90 min 3 – 4 hr 2 – 3 times / day or more

Advantages of Ultra short vs Short Insulin: Rapid onset of action ( patients will not wait long before they eat ). Its duration of action is no longer than 3-4 hrs regardless of the dose: Decreased risk of hyper insulinemia. Decreased risk of postprandial hypoglycemia.

Intermediate acting insulins e.g.Isophane (NPH), Lente insulin Turbid suspension at neutral pH Given S.C. only Onset of action 1-2 h. Peak serum level 5-7 h. Duration of action 13-18 h. Not used in emergencies (diabetic ketoacidosis). Insulin mixtures 75/25 - 70/30 - 50/50 (NPH/regular). (NPL= NPH / lispro)(NPA= NPH / aspart)

Mixture of 30% semilente + 70% ultralente insulin Turbid suspension at neutral pH Given S.C. only. onset of action (1-3 h) Peak serum level 4-8 h. Duration of action 13-20 h. Lente and NPH insulins are equivalent in activity. Not used in emergencies (diabetic ketoacidosis). Should not be mixed with insulin in the same syringe.

Long acting insulins Insulin glargine (lantus),Insulin detemir(Levemir) Clear solution Slow onset of action 2 h. Given s.c. only Maximum effect after 4-5 h produce peakless activity profile** Prolonged duration of action (24 h). Should not be mixed with other insulin Used in type 1 and type 2 diabetes.

Advantages of Insulin glargine over intermediate-acting insulins Constant circulating insulin over 24 hr with no pronounced peak. More safe than NPH & Lente insulins ( reduced risk of hypoglycemia). Clear solution(not require resuspension before use)

Glargine NPH NPH vs Glargine

Routes of administrations of insulin Can not be given orally (why ?) Insulin syringes, s.c.(arms, abdomen, thighs). Portable pin injector (pre-filled). Continuous S.C. infusion (insulin pump). More convenient Eliminate multiple daily injection Programmed to deliver basal rate of insulin.

Pin injector Insulin pump

Insulin degradation Half life of circulating insulin is 3-5 min. 60% liver & 40% kidney (endogenous insulin) 60% kidney & 40% liver (exogenous insulin) Should be stored in refrigerator& warm up to room temp before use. Must be used within 30 days.

Complications of Insulin Therapy: People with diabetes should have a medical ID with them at all times Hypoglycemia(life threatening occurs when blood glucose < 50 mg/dl.) Overdose of insulin Excessive (unusual) physical exercise A meal is missed How it is treated? 1. Conscious patient: Oral glucose tablets, juice or honey. 2. Unconscious patient: 20-50 ml of 50% glucose solution I.V. infusion, OR Glucagon (1 mg S.C. or I.M.) Weight gain Lipodystrophy & Lipohypertrophy at injection site Hypokalaemia